<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:bx="http://bx.businessweek.com">
<title>Pharmaceuticals Companies - Business Exchange</title>
<subtitle>Most Active Articles</subtitle>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/most-active/feed" rel="self"/>
<link href="http://bx.businessweek.com/pharmaceuticals-companies"/>
<updated>2013-05-21T06:07:08.683-04:00</updated>
<author>
<name>Business Exchange</name>
<email>Business_Exchange@businessweek.com</email>
</author>
<id>urn:com:businessweek:bx:topic:most-active:pharmaceuticals-companies</id>
<bx:suggester>
<bx:fullname>Henri TCHEN</bx:fullname>
<bx:id>htchen963</bx:id>
<bx:link href="http://bx.businessweek.com/profile/henri-tchen/htchen963/"/>
</bx:suggester>
<entry>
<title>The Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/the-global-molecular-diagnostics-market-to-grow-at-a-cagr-of-1142-percent-over-the-period-2012-2016/16920154838038349531-60e537041aa08ab3ed1a94797b72d166/"/>
<id>urn:com:businessweek:bx:article:16920154838038349531-60e537041aa08ab3ed1a94797b72d166</id>
<updated>2013-05-16T06:56:44.520-04:00</updated>
<summary>One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment......</summary>
<content type="html">One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment......</content>
<source>
<title>bharatbook.com</title>
</source>
<bx:external-link>http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/global-molecular-diagnostics-market-2012-2016.html</bx:external-link>
<bx:adder>
<bx:fullname>Ross Taylor</bx:fullname>
<bx:id>bbook094</bx:id>
<bx:link href="http://bx.businessweek.com/profile/ross-taylor/bbook094/"/>
</bx:adder>
<bx:action>
<bx:total>0</bx:total>
<bx:view>0</bx:view>
<bx:save>0</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>12 Overused Business Cliches</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/12-overused-business-cliches/14384056891357441019-c26722320212c47c3871652ada84f6e2/"/>
<id>urn:com:businessweek:bx:article:14384056891357441019-c26722320212c47c3871652ada84f6e2</id>
<updated>2012-06-25T08:07:00.885-04:00</updated>
<summary>Here are a few business cliches that have no meaning or importance. Try not to use these unless you want to bomb in your presentations or speeches</summary>
<content type="html">Here are a few business cliches that have no meaning or importance. Try not to use these unless you want to bomb in your presentations or speeches</content>
<source>
<title>amgtconsulting.blogspot.com</title>
</source>
<bx:external-link>http://amgtconsulting.blogspot.com/2012/06/12-overused-business-cliches-john-j.html</bx:external-link>
<bx:adder>
<bx:fullname>John J. Arent</bx:fullname>
<bx:id>jarent632</bx:id>
<bx:link href="http://bx.businessweek.com/profile/johnj-arent/jarent632/"/>
</bx:adder>
<bx:action>
<bx:total>8</bx:total>
<bx:view>1</bx:view>
<bx:save>0</bx:save>
<bx:reaction>7</bx:reaction>
</bx:action>
</entry>
<entry>
<title>INNOVATION killers by John J Arent</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/innovation-killers-by-john-j-arent/12717656315944316608-99ed51d267b8c489c3dd1c60084d2740/"/>
<id>urn:com:businessweek:bx:article:12717656315944316608-99ed51d267b8c489c3dd1c60084d2740</id>
<updated>2012-06-19T10:18:02.306-04:00</updated>
<summary>If you want to succeed, look at your leadership. there are some leaders who are not open to innovation. Here are three main attributes to look for.</summary>
<content type="html">If you want to succeed, look at your leadership. there are some leaders who are not open to innovation. Here are three main attributes to look for.</content>
<source>
<title>amgtconsulting.blogspot.com</title>
</source>
<bx:external-link>http://amgtconsulting.blogspot.com/2012/06/innovation-killers-by-john-j-arent.html</bx:external-link>
<bx:adder>
<bx:fullname>John J. Arent</bx:fullname>
<bx:id>jarent632</bx:id>
<bx:link href="http://bx.businessweek.com/profile/johnj-arent/jarent632/"/>
</bx:adder>
<bx:action>
<bx:total>11</bx:total>
<bx:view>0</bx:view>
<bx:save>0</bx:save>
<bx:reaction>11</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Sanofi Pasteur’s New Influenza Vaccine</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/sanofi-pasteurs-new-influenza-vaccine/4357329633693891198-0552fba0791c4e9ac0aeb52633ada488/"/>
<id>urn:com:businessweek:bx:article:4357329633693891198-0552fba0791c4e9ac0aeb52633ada488</id>
<updated>2011-09-20T01:42:20.680-04:00</updated>
<summary>Fluzone Intradermal vaccine, licensed by the U.S. Food and Drug Administration (FDA), is claimed to be the first influenza vaccine in the U.S. that uses a microinjection system for intradermal delivery.</summary>
<content type="html">Fluzone Intradermal vaccine, licensed by the U.S. Food and Drug Administration (FDA), is claimed to be the first influenza vaccine in the U.S. that uses a microinjection system for intradermal delivery.</content>
<source>
<title>ramanmedianetwork.com</title>
</source>
<bx:external-link>http://www.ramanmedianetwork.com/sanofi-pasteur%e2%80%99s-new-intradermal-influenza-vaccine/</bx:external-link>
<bx:adder>
<bx:fullname>Rakesh Raman</bx:fullname>
<bx:id>rraman103</bx:id>
<bx:link href="http://bx.businessweek.com/profile/rakesh-raman/rraman103/"/>
</bx:adder>
<bx:action>
<bx:total>35</bx:total>
<bx:view>32</bx:view>
<bx:save>2</bx:save>
<bx:reaction>1</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Why These Ten Companies Should Let Go of Their CEOs in 2009</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/why-these-ten-companies-should-let-go-of-their-ceos-in-2009/4947136885381980922-2592b8be466a2e0b13895a87a1f2bccb/"/>
<id>urn:com:businessweek:bx:article:4947136885381980922-2592b8be466a2e0b13895a87a1f2bccb</id>
<updated>2008-12-06T13:17:54.339-05:00</updated>
<summary>Each year we come out with a list of companies who should get rid of their CEOs or which should make some strategic changes inside the company that revolve around the CEO and management.</summary>
<content type="html">Each year we come out with a list of companies who should get rid of their CEOs or which should make some strategic changes inside the company that revolve around the CEO and management.</content>
<source>
<title>247wallst.com</title>
</source>
<bx:external-link>http://www.247wallst.com/2008/12/10-ceos-to-go-8.html</bx:external-link>
<bx:adder>
<bx:fullname>Ashley Allen</bx:fullname>
<bx:id>aallen237</bx:id>
<bx:link href="http://bx.businessweek.com/profile/ashley-allen/aallen237/"/>
</bx:adder>
<bx:action>
<bx:total>245</bx:total>
<bx:view>244</bx:view>
<bx:save>1</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Current Developmental Pipeline Review Of Aragon Pharmaceuticals, Inc.</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/current-developmental-pipeline-review-of-aragon-pharmaceuticals-inc/11873183326960856714-276c29ae546184700fd2c37e4d7f331b/"/>
<id>urn:com:businessweek:bx:article:11873183326960856714-276c29ae546184700fd2c37e4d7f331b</id>
<updated>2013-01-23T00:56:08.892-05:00</updated>
<summary>Summary of direction therapeutics across various treatment places.</summary>
<content type="html">Summary of direction therapeutics across various treatment places.</content>
<source>
<title>companyprofilesandconferences.com</title>
</source>
<bx:external-link>http://www.companyprofilesandconferences.com/researchindex/Pharmaceuticals-Healthcare-c13/Aragon-Pharmaceuticals-Inc-Product-Pipeline-Review-.html</bx:external-link>
<bx:adder>
<bx:fullname>Raja Iyer</bx:fullname>
<bx:id>riyer567</bx:id>
<bx:link href="http://bx.businessweek.com/profile/raja-iyer/riyer567/"/>
</bx:adder>
<bx:action>
<bx:total>1</bx:total>
<bx:view>1</bx:view>
<bx:save>0</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Global Pharma Innovation at Abbott</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/global-pharma-innovation-at-abbott/12475428677869852344-f63fda181c480c31b8e64ca046309d16/"/>
<id>urn:com:businessweek:bx:article:12475428677869852344-f63fda181c480c31b8e64ca046309d16</id>
<updated>2011-11-25T18:21:18.528-05:00</updated>
<summary>Tom Mottola, Senior Business Systems Manager at Abbott, a global pharmaceuticals and health care products company, presents on innovation management best practices.</summary>
<content type="html">Tom Mottola, Senior Business Systems Manager at Abbott, a global pharmaceuticals and health care products company, presents on innovation management best practices.</content>
<source>
<title>innovationexcellence.com</title>
</source>
<bx:external-link>http://www.innovationexcellence.com/blog/2011/11/24/global-pharma-innovation-at-abbott/</bx:external-link>
<bx:adder>
<bx:fullname>Braden Kelley</bx:fullname>
<bx:id>bkelley034</bx:id>
<bx:link href="http://bx.businessweek.com/profile/braden-kelley/bkelley034/"/>
</bx:adder>
<bx:action>
<bx:total>19</bx:total>
<bx:view>18</bx:view>
<bx:save>1</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Hepalink Pharmaceutical: profit declined in 2011H1, influenced by export price shrink of heparin APIs-ResearchInChina</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/hepalink-pharmaceutical-profit-declined-in-2011h1-influenced-by-export-price-shrink-of-heparin-apis-researchinchina/18388587965669875115-a7d26af1701158e459bd01a320878007/"/>
<id>urn:com:businessweek:bx:article:18388587965669875115-a7d26af1701158e459bd01a320878007</id>
<updated>2011-09-25T22:58:56.584-04:00</updated>
<summary></summary>
<content type="html"></content>
<source>
<title>researchinchina.com</title>
</source>
<bx:external-link>http://www.researchinchina.com/News/NewsContent.aspx?id=23343</bx:external-link>
<bx:adder>
<bx:fullname>Chen Li</bx:fullname>
<bx:id>clee290</bx:id>
<bx:link href="http://bx.businessweek.com/profile/chen-li/clee290/"/>
</bx:adder>
<bx:action>
<bx:total>15</bx:total>
<bx:view>13</bx:view>
<bx:save>1</bx:save>
<bx:reaction>1</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Pharmaceutical Company Outlook to 2013</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/pharmaceutical-company-outlook-to-2013/2298229308034517507-0af4f4834d056aede85f9618adcad1a8/"/>
<id>urn:com:businessweek:bx:article:2298229308034517507-0af4f4834d056aede85f9618adcad1a8</id>
<updated>2009-02-18T06:55:00.000-05:00</updated>
<summary>molecule type analysis 20 PharmaVitae Universe M&amp;A analysis 23 PharmaVitae Universe operating performance analysis 25 CHAPTER 2 THE BIG PHARMA OUTLOOK TO 2013 30 Key findings 30 Overview of Big Pharma to 2013 31 Big Pharma Rx pharma sales</summary>
<content type="html">molecule type analysis 20 PharmaVitae Universe M&amp;A analysis 23 PharmaVitae Universe operating performance analysis 25 CHAPTER 2 THE BIG PHARMA OUTLOOK TO 2013 30 Key findings 30 Overview of Big Pharma to 2013 31 Big Pharma Rx pharma sales</content>
<source>
<title>Reuters</title>
</source>
<bx:external-link>http://c.moreover.com/click/here.pl?r1826713827&amp;f=9791</bx:external-link>
<bx:adder>
<bx:fullname></bx:fullname>
<bx:id></bx:id>
<bx:link href=""/>
</bx:adder>
<bx:action>
<bx:total>216</bx:total>
<bx:view>213</bx:view>
<bx:save>2</bx:save>
<bx:reaction>1</bx:reaction>
</bx:action>
</entry>
<entry>
<title>FDA Takes action against MADE</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/fda-takes-action-against-made/18229471741299172562-a6cd2a5d030bcdf3ebd9fc7b99d8961a/"/>
<id>urn:com:businessweek:bx:article:18229471741299172562-a6cd2a5d030bcdf3ebd9fc7b99d8961a</id>
<updated>2011-11-29T14:53:45.619-05:00</updated>
<summary>The Food and Drug Administration is taking actions against nutraceutical producer MADE (Manufacturing ATF Dedicated Excellence, Inc.) The action is driven for…</summary>
<content type="html">The Food and Drug Administration is taking actions against nutraceutical producer MADE (Manufacturing ATF Dedicated Excellence, Inc.) The action is driven for…</content>
<source>
<title>ecomm-unity.com</title>
</source>
<bx:external-link>http://www.ecomm-unity.com/group/herbalsupplementsinpayments/forum/topics/fda-takes-action-against-made</bx:external-link>
<bx:adder>
<bx:fullname>Daniel Berger</bx:fullname>
<bx:id>dberger532</bx:id>
<bx:link href="http://bx.businessweek.com/profile/daniel-berger/dberger532/"/>
</bx:adder>
<bx:action>
<bx:total>9</bx:total>
<bx:view>7</bx:view>
<bx:save>1</bx:save>
<bx:reaction>1</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Pfizer to Sell Lipitor Directly to Patients After Patent Expires</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/pfizer-to-sell-lipitor-directly-to-patients-after-patent-expires/3407640104938722504-3b993e6e4e8238dd3eea0b59e6a95ed8/"/>
<id>urn:com:businessweek:bx:article:3407640104938722504-3b993e6e4e8238dd3eea0b59e6a95ed8</id>
<updated>2011-11-22T23:01:11.616-05:00</updated>
<summary>Pfizer is planning to sell Lipitor at generic prices directly to patients, part of an effort to hold onto sales of cholesterol fighter after the drug loses patent protection.</summary>
<content type="html">Pfizer is planning to sell Lipitor at generic prices directly to patients, part of an effort to hold onto sales of cholesterol fighter after the drug loses patent protection.</content>
<source>
<title>online.wsj.com</title>
</source>
<bx:external-link>http://online.wsj.com/article/SB10001424052970203710704577052350701638614.html</bx:external-link>
<bx:adder>
<bx:fullname>Peter Sonnenreich</bx:fullname>
<bx:id>psonnenreich277</bx:id>
<bx:link href="http://bx.businessweek.com/profile/peter-sonnenreich/psonnenreich277/"/>
</bx:adder>
<bx:action>
<bx:total>20</bx:total>
<bx:view>19</bx:view>
<bx:save>1</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Arent Management Consulting: Michael J. Fox</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/arent-management-consulting-michael-j-fox/5138350254908299806-0c46718d61e8af70474659d3deb13d40/"/>
<id>urn:com:businessweek:bx:article:5138350254908299806-0c46718d61e8af70474659d3deb13d40</id>
<updated>2012-05-21T09:13:51.357-04:00</updated>
<summary></summary>
<content type="html"></content>
<source>
<title>amgtconsulting.blogspot.com</title>
</source>
<bx:external-link>http://amgtconsulting.blogspot.com/2012/05/michael-j-fox-canadian-american.html</bx:external-link>
<bx:adder>
<bx:fullname>John J. Arent</bx:fullname>
<bx:id>jarent632</bx:id>
<bx:link href="http://bx.businessweek.com/profile/johnj-arent/jarent632/"/>
</bx:adder>
<bx:action>
<bx:total>2</bx:total>
<bx:view>1</bx:view>
<bx:save>0</bx:save>
<bx:reaction>1</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Big Pharma Launches a Talent Raid in China</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/big-pharma-launches-a-talent-raid-in-china/2415087823346732091-8dcba5c44ad925cc5072e4f4a16de282/"/>
<id>urn:com:businessweek:bx:article:2415087823346732091-8dcba5c44ad925cc5072e4f4a16de282</id>
<updated>2011-07-15T10:52:43.424-04:00</updated>
<summary>Foreign drug companies lure underpaid Chinese doctors with raises</summary>
<content type="html">Foreign drug companies lure underpaid Chinese doctors with raises</content>
<source>
<title>BusinessWeek</title>
</source>
<bx:external-link>http://www.businessweek.com/magazine/big-pharma-launches-a-talent-raid-in-china-07142011.html</bx:external-link>
<bx:adder>
<bx:fullname>I.J. Ikavalko</bx:fullname>
<bx:id>iikavalko154</bx:id>
<bx:link href="http://bx.businessweek.com/profile/ij-ikavalko/iikavalko154/"/>
</bx:adder>
<bx:action>
<bx:total>21</bx:total>
<bx:view>20</bx:view>
<bx:save>1</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Pharmaceuticals for Free</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/pharmaceuticals-for-free/11073545522355194816-95a5a002b5cf2abaf2afc5664206a7f0/"/>
<id>urn:com:businessweek:bx:article:11073545522355194816-95a5a002b5cf2abaf2afc5664206a7f0</id>
<updated>2011-11-09T14:48:47.122-05:00</updated>
<summary>As pharmaceutical companies begin to implement initiative such as patent pooling and providing cheap consumer drugs to the developing world, just what’s behind this new ‘ethical pharma.’ And can it really work?</summary>
<content type="html">As pharmaceutical companies begin to implement initiative such as patent pooling and providing cheap consumer drugs to the developing world, just what’s behind this new ‘ethical pharma.’ And can it really work?</content>
<source>
<title>thebeginner.eu</title>
</source>
<bx:external-link>http://www.thebeginner.eu/business/632-pharmaceuticals-for-free</bx:external-link>
<bx:adder>
<bx:fullname>Ani Atanasova</bx:fullname>
<bx:id>aatanasova087</bx:id>
<bx:link href="http://bx.businessweek.com/profile/ani-atanasova/aatanasova087/"/>
</bx:adder>
<bx:action>
<bx:total>20</bx:total>
<bx:view>18</bx:view>
<bx:save>1</bx:save>
<bx:reaction>1</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Roger Bate: Beware the Risks of Generic Drugs</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/roger-bate-beware-the-risks-of-generic-drugs/7396258985709711002-bb215f6cab71e70913d76b08ca9132ac/"/>
<id>urn:com:businessweek:bx:article:7396258985709711002-bb215f6cab71e70913d76b08ca9132ac</id>
<updated>2011-07-06T00:20:08.827-04:00</updated>
<summary>In The Wall Street Journal, Roger Bate reports that pharmaceutical chemicals—particularly those manufactured from ingredients in China—are often substandard or tainted.</summary>
<content type="html">In The Wall Street Journal, Roger Bate reports that pharmaceutical chemicals—particularly those manufactured from ingredients in China—are often substandard or tainted.</content>
<source>
<title>online.wsj.com</title>
</source>
<bx:external-link>http://online.wsj.com/article/SB10001424052702303339904576406163574698214.html?mod=WSJ_Opinion_LEFTTopOpinion&amp;mg=com-wsj</bx:external-link>
<bx:adder>
<bx:fullname>Peter Sonnenreich</bx:fullname>
<bx:id>psonnenreich277</bx:id>
<bx:link href="http://bx.businessweek.com/profile/peter-sonnenreich/psonnenreich277/"/>
</bx:adder>
<bx:action>
<bx:total>23</bx:total>
<bx:view>21</bx:view>
<bx:save>1</bx:save>
<bx:reaction>1</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Drug Mergers: Killers for Research</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/drug-mergers-killers-for-research/2360515815255126107-a0947cef48fb72fe5097aa4cc8f69652/"/>
<id>urn:com:businessweek:bx:article:2360515815255126107-a0947cef48fb72fe5097aa4cc8f69652</id>
<updated>2009-03-09T23:26:16.844-04:00</updated>
<summary>Merck&#39;s decision to acquire Schering-Plough (SGP) for $41 billion will improve its bottom line over the next two to three years, as the merged company cuts at least 16,000 staffers and streamlines its operating costs. Further out, however, Merck...</summary>
<content type="html">Merck&#39;s decision to acquire Schering-Plough (SGP) for $41 billion will improve its bottom line over the next two to three years, as the merged company cuts at least 16,000 staffers and streamlines its operating costs. Further out, however, Merck...</content>
<source>
<title>BusinessWeek</title>
</source>
<bx:external-link>http://www.businessweek.com/technology/content/mar2009/tc2009039_020072.htm?chan=top+news_top+news+index+-+temp_top+story</bx:external-link>
<bx:adder>
<bx:fullname>John A. Byrne</bx:fullname>
<bx:id>jbyrne076</bx:id>
<bx:link href="http://bx.businessweek.com/profile/johna-byrne/jbyrne076/"/>
</bx:adder>
<bx:action>
<bx:total>84</bx:total>
<bx:view>81</bx:view>
<bx:save>3</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Merck&#39;s Risky Bet on Heart Drugs May Yield Lipitor-Like Success - Bloomberg</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/mercks-risky-bet-on-heart-drugs-may-yield-lipitor-like-success---bloomberg/9787555923900204054-49b9ac1e2f115b4f6c8b382295ea9f52/"/>
<id>urn:com:businessweek:bx:article:9787555923900204054-49b9ac1e2f115b4f6c8b382295ea9f52</id>
<updated>2010-11-29T23:45:55.723-05:00</updated>
<summary>When Pfizer Inc. abandoned a cholesterol pill four years ago after spending $1 billion to develop it, Richard Clark , Merck &amp; Co. ’s chief executive officer, was tempted to give up on a similar drug in testing.</summary>
<content type="html">When Pfizer Inc. abandoned a cholesterol pill four years ago after spending $1 billion to develop it, Richard Clark , Merck &amp; Co. ’s chief executive officer, was tempted to give up on a similar drug in testing.</content>
<source>
<title>bloomberg.com</title>
</source>
<bx:external-link>http://www.bloomberg.com/news/2010-11-24/merck-s-risky-bet-on-heart-drugs-may-yield-pills-with-lipitor-like-success.html</bx:external-link>
<bx:adder>
<bx:fullname>I.J. Ikavalko</bx:fullname>
<bx:id>iikavalko154</bx:id>
<bx:link href="http://bx.businessweek.com/profile/ij-ikavalko/iikavalko154/"/>
</bx:adder>
<bx:action>
<bx:total>53</bx:total>
<bx:view>52</bx:view>
<bx:save>1</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Creating effective Mission, Vision, and Values Statements for biotechnology and pharmaceutical companies</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/creating-effective-mission-vision-and-values-statements-for-biotechnology-and-pharmaceutical-companies/12779589592522054501-b0c9d085197c79b54f435b8903a37c46/"/>
<id>urn:com:businessweek:bx:article:12779589592522054501-b0c9d085197c79b54f435b8903a37c46</id>
<updated>2011-11-17T10:14:03.759-05:00</updated>
<summary>Mission, Vision, and Values Statements are the most fundamental elements of strategic planning for a business or organization.</summary>
<content type="html">Mission, Vision, and Values Statements are the most fundamental elements of strategic planning for a business or organization.</content>
<source>
<title>bioedgeconsulting.com</title>
</source>
<bx:external-link>http://www.bioedgeconsulting.com/blog/creating-effective-mission-vision-and-values-statements-for-biotechnology-and-pharmaceutical-companies.html</bx:external-link>
<bx:adder>
<bx:fullname>Jessica Okonkowski Josefsberg</bx:fullname>
<bx:id>jjosefsberg086</bx:id>
<bx:link href="http://bx.businessweek.com/profile/jessicaokonkowski-josefsberg/jjosefsberg086/"/>
</bx:adder>
<bx:action>
<bx:total>9</bx:total>
<bx:view>7</bx:view>
<bx:save>1</bx:save>
<bx:reaction>1</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Targeting Aggressive Forms of Cancer: Sunshine Biopharma (OTCBB: SBFM) and Roche (SIX: RO, ROG; OTCQX: RHHBY)</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/targeting-aggressive-forms-of-cancer-sunshine-biopharma-otcbb-sbfm-and-roche-six-ro-rog-otcqx-rhhby/3184870005942409281-b510fceceb33a00a5a8d36bce680e8d9/"/>
<id>urn:com:businessweek:bx:article:3184870005942409281-b510fceceb33a00a5a8d36bce680e8d9</id>
<updated>2012-07-09T09:55:55.607-04:00</updated>
<summary></summary>
<content type="html"></content>
<source>
<title>investorideas.com</title>
</source>
<bx:external-link>http://www.investorideas.com/CO/SBFM/news/2012/07091.asp</bx:external-link>
<bx:adder>
<bx:fullname>Dawn Van Zant</bx:fullname>
<bx:id>dvanzant229</bx:id>
<bx:link href="http://bx.businessweek.com/profile/dawn-vanzant/dvanzant229/"/>
</bx:adder>
<bx:action>
<bx:total>1</bx:total>
<bx:view>1</bx:view>
<bx:save>0</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>CVS to pay $55,000 to settle bias case</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/cvs-to-pay-55000-to-settle-bias-case/15272013706536220861-1e0871c546be6891d3016bcdbbe6739d/"/>
<id>urn:com:businessweek:bx:article:15272013706536220861-1e0871c546be6891d3016bcdbbe6739d</id>
<updated>2011-06-03T09:50:24.613-04:00</updated>
<summary>The new owners of Longs Drugs have agreed to pay $55,000 to settle a claim of race and sex discrimination by a woman who worked as a product buyer at Longs&#39; headquarters in Antioch, the U.S. Equal Employment Opportunity...</summary>
<content type="html">The new owners of Longs Drugs have agreed to pay $55,000 to settle a claim of race and sex discrimination by a woman who worked as a product buyer at Longs&#39; headquarters in Antioch, the U.S. Equal Employment Opportunity...</content>
<source>
<title>San Francisco Chronicle</title>
</source>
<bx:external-link>http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2011/05/31/BUG41JNMJI.DTL</bx:external-link>
<bx:adder>
<bx:fullname>Michael P. Ehline, Esq.</bx:fullname>
<bx:id>mehline538</bx:id>
<bx:link href="http://bx.businessweek.com/profile/michaelp-ehlineesq/mehline538/"/>
</bx:adder>
<bx:action>
<bx:total>11</bx:total>
<bx:view>8</bx:view>
<bx:save>2</bx:save>
<bx:reaction>1</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Hualan Biological Engineering’s vaccine performance declined in 2011H1, blood product business expected to be favorable -ResearchInChina</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/hualan-biological-engineerings-vaccine-performance-declined-in-2011h1-blood-product-business-expected-to-be-favorable--researchinchina/5115970782755833893-09f78a4da14936c6f162fa29b478067d/"/>
<id>urn:com:businessweek:bx:article:5115970782755833893-09f78a4da14936c6f162fa29b478067d</id>
<updated>2011-09-25T23:08:48.665-04:00</updated>
<summary></summary>
<content type="html"></content>
<source>
<title>researchinchina.com</title>
</source>
<bx:external-link>http://www.researchinchina.com/News/NewsContent.aspx?id=22043</bx:external-link>
<bx:adder>
<bx:fullname>Chen Li</bx:fullname>
<bx:id>clee290</bx:id>
<bx:link href="http://bx.businessweek.com/profile/chen-li/clee290/"/>
</bx:adder>
<bx:action>
<bx:total>3</bx:total>
<bx:view>2</bx:view>
<bx:save>1</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Partnerships in Clinical Trials: 52 Perspectives: “Clinical Research in Latin America”</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/partnerships-in-clinical-trials-52-perspectives-clinical-research-in-latin-america/7424511544665840782-a86f23d323817ace2cee2849aaa7af97/"/>
<id>urn:com:businessweek:bx:article:7424511544665840782-a86f23d323817ace2cee2849aaa7af97</id>
<updated>2011-05-16T11:20:58.075-04:00</updated>
<summary></summary>
<content type="html"></content>
<source>
<title>partnershipswithcros.blogspot.com</title>
</source>
<bx:external-link>http://partnershipswithcros.blogspot.com/2011/05/52-perspectives-clinical-research-in.html</bx:external-link>
<bx:adder>
<bx:fullname>Jennifer Pereira</bx:fullname>
<bx:id>jpereira869</bx:id>
<bx:link href="http://bx.businessweek.com/profile/jennifer-pereira/jpereira869/"/>
</bx:adder>
<bx:action>
<bx:total>15</bx:total>
<bx:view>13</bx:view>
<bx:save>2</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>Roche, Daiichi Sankyo Win U.S. Approval on Drug to Treat Advanced Melanoma</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/roche-daiichi-sankyo-win-us-approval-on-drug-to-treat-advanced-melanoma/9080372117349878321-c96b6167abe4874257ef3de438b6358d/"/>
<id>urn:com:businessweek:bx:article:9080372117349878321-c96b6167abe4874257ef3de438b6358d</id>
<updated>2011-08-17T15:59:41.848-04:00</updated>
<summary>Roche Holding AG and Daiichi Sankyo Co. won U.S. clearance to sell a pill for melanoma that is among a new wave of medicines developed to fight the deadliest form of skin cancer.</summary>
<content type="html">Roche Holding AG and Daiichi Sankyo Co. won U.S. clearance to sell a pill for melanoma that is among a new wave of medicines developed to fight the deadliest form of skin cancer.</content>
<source>
<title>bloomberg.com</title>
</source>
<bx:external-link>http://www.bloomberg.com/news/2011-08-17/roche-daiichi-sankyo-win-u-s-approval-on-drug-to-treat-advanced-melanoma.html</bx:external-link>
<bx:adder>
<bx:fullname>I.J. Ikavalko</bx:fullname>
<bx:id>iikavalko154</bx:id>
<bx:link href="http://bx.businessweek.com/profile/ij-ikavalko/iikavalko154/"/>
</bx:adder>
<bx:action>
<bx:total>9</bx:total>
<bx:view>8</bx:view>
<bx:save>1</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
<entry>
<title>This is the new business model for pharma?</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/this-is-the-new-business-model-for-pharma/9949637950790092870-ba36cfb0130dd0a8b0f2fbd6c72573fe/"/>
<id>urn:com:businessweek:bx:article:9949637950790092870-ba36cfb0130dd0a8b0f2fbd6c72573fe</id>
<updated>2008-10-02T12:22:00.000-04:00</updated>
<summary>Cash starved companies are going to ... of bureaucratic big pharma processes that slow drug</summary>
<content type="html">Cash starved companies are going to ... of bureaucratic big pharma processes that slow drug</content>
<source>
<title>World of DTC Marketing</title>
</source>
<bx:external-link>http://www.worldofdtcmarketing.com/files/b5edd83854e70dc1cc3fe8ae8b5d281f-462.html</bx:external-link>
<bx:adder>
<bx:fullname></bx:fullname>
<bx:id></bx:id>
<bx:link href=""/>
</bx:adder>
<bx:action>
<bx:total>89</bx:total>
<bx:view>87</bx:view>
<bx:save>1</bx:save>
<bx:reaction>1</bx:reaction>
</bx:action>
</entry>
<entry>
<title>North China Pharmaceutical Co., Ltd. (600812.SH) received approval in recombinant human albumin, which is expected to significantly enhance the performance-ResearchInChina</title>
<link href="http://bx.businessweek.com/pharmaceuticals-companies/north-china-pharmaceutical-co-ltd-600812sh-received-approval-in-recombinant-human-albumin-which-is-expected-to-significantly-enhance-the-performance-researchinchina/11741541039371427742-ba80b174581a22964fba62362ce9599c/"/>
<id>urn:com:businessweek:bx:article:11741541039371427742-ba80b174581a22964fba62362ce9599c</id>
<updated>2011-09-25T23:29:21.538-04:00</updated>
<summary></summary>
<content type="html"></content>
<source>
<title>researchinchina.com</title>
</source>
<bx:external-link>http://www.researchinchina.com/News/NewsContent.aspx?id=23571</bx:external-link>
<bx:adder>
<bx:fullname>Chen Li</bx:fullname>
<bx:id>clee290</bx:id>
<bx:link href="http://bx.businessweek.com/profile/chen-li/clee290/"/>
</bx:adder>
<bx:action>
<bx:total>7</bx:total>
<bx:view>6</bx:view>
<bx:save>1</bx:save>
<bx:reaction>0</bx:reaction>
</bx:action>
</entry>
</feed>